5th microbiome r&d business collaboration congress · 5 th microbiome r&d & business...

5TH MICROBIOME R&D & BUSINESS COLLABORATION CONGRESS

4TH PROBIOTICS CONGRESS: ASIASATELLITE MEETING: TAIWAN MICROBIOME CONGRESS

www.global-engage .com

6 - 7 M a r c h 2 0 1 9REGENT TAIPEI,TAIWAN

Co-Hosts

5TH MICROBIOME R&D & BUSINESS COLLABORATION CONGRESS / 4TH PROBIOTICS CONGRESS: ASIA 2019

Global Engage is pleased to announce, as part of their worldwide microbiome series, the 5th Microbiome R&D and Business Collaboration Congress and co-located 4th Probiotics Congress which will be held on March 6-7, 2019 at the Regent Taipei, Taiwan. Co-hosted with the National Central University and National Chiao Tung University (GLORIA) of Taiwan, the congresses will bring together industry and academic delegates to discuss the latest microbiome research, the development of partnerships and commercial collaborations in this area and the expected growth of product pipelines.Recent microbiome research has demonstrated the important role that communities of microorganisms play on human body. This area of research, associated with immunity and behavioural traits, is paramount in maintaining our health and keeping us away from disease. With numerous pre-clinical and clinical studies being conducted, microbiome is transitioning from a descriptive to a more mechanistic science. It is inevitable that microbiome is a promising prospect to improve human health, as it enables us to step forward and manipulate microbiota in a variety of ways. With the growing interest in the area, research experts and industry players are working together towards bringing microbiome discoveries to the market, making it an unprecedented investment opportunity alongside large-scale collaborations underway and sequencing data placed in the public domain. Due to this reason, microbiome is now set to make waves in the science and medical world as an essential prerequisite for future rational interventions.

Attracting over 300 delegates, the co-located meetings will promote comprehensive understanding and reciprocal benefits of the latest scientific and business developments in microbiome and probiotics. The 2-day interactive meeting will highlight cutting edge research and business case studies through expert presentations, and panel discussions exploring key issues in the subject area, an exhibition filled with solution providers showcasing their products and solutions, as well as networking breaks to promote interactions and business reach with fellow peers.

Having a diverged group of professionals interested in microbiome and probiotics, both scientific and industry talks will take place at this event. Topic areas to be addressed include microbiome in health and disease, skin microbiome, probiotics and brain health amongst others as well as the regulatory issues associated with these areas of research. It is hoped that the meetings will further develop the microbiome and probiotics research, as well as foster more collaborations and commercialisation of the areas in Asia.

JACK GILBERTFaculty Director, The Microbiome

Center and Professor, Department of Surgery, University of Chicago,

USA | Founder, The Earth Microbiome Project and Co-

Founder, American Gut Project

ANDERS DAMHOLTHead of Clinical Development,

Human Health Innovation,Chr. Hansen A/S, Germany

NICOLE ROYPrincipal Scientist and Science

Team Leader, AgResearch, New Zealand

YASUHIRO KOGA President, Japanese Society

for Probiotic Science

DAR-BIN SHIEHDeputy Minister, Ministry of Science

and Technology Distinguished Professor, Institute of Oral Medicine,

National Cheng Kung University College of Medicine National Cheng

Kung University, Taiwan

MING-JU CHEN Professor, Department of Animal Science and Technology, National

Taiwan University, Taiwan and President, Taiwan Association of

Lactic Acid Bacteria

MARGARET MORRISProfessor and Head of

Pharmacology, University of New South Wales, Australia

HANNA SIDJABATHonorary Fellow and Chief Investigator, University of

Queensland Centre for Clinical Research, Australia

WARM WELCOME

MICROBIOME DISCOVERIES

• Latest updates on the microbiome movement in Asia and across the globe

• Tools and techniques for studying microbiome• Metagenomics• Sequencing method / bioinformatics

MICROBIOME IN HEALTH AND DISEASE

• Relationship between obesity and metabolic disease• Inflammation• Gut-brain axis• Enteric infection/microbiome pathogen interactions• Case studies such as IBD, diabetes, obesity, colitis• Antibiotics resistance• Infant gut microbiome

MICROBIOME-BASED THERAPIES

• Drug delivery• Faecal microbiome transplant• Biomarker / Clinical Development

COMMERCIALISATION OF MICROBIOME AND PROBIOTICS

• Developing business relationships between academia & pharma• Collaborations/partnerships – the global scope of microbiome

research/structuring successful collaborations • Bringing live microbial products to market – IP, regulation, GMP • Pharmaceutical involvement and therapeutic development • Probiotic strain identification, designation and safety

OUTSIDE THE GUT

• Skin microbiome• Strategies and tools for studying skin microbiome• Case studies on acne, eczema, atopic dermatitis,

wound health & cosmetic applications• Women’s health

• Host-interactions, vaginal microbiome, preterm birth and pregnancy progression

• Gut-brain axis• Oral and respiratory microbiome research

PROBIOTICS R&D

• Strain discovery• Gut-pathogen interactions • Role of probiotics in IBS management • Antibiotic exposure & multidrug resistance • Role of probiotics as anti-diarrhoeal agents • Efficacy and effectiveness of different strains • Biocontrol of gut pathogens with probiotics • Probiotics and the gut-brain axis • Probiotics and skin• Probiotics and allergy / disease• Food and fermentation

PAEDIATRICS

• Milk-oriented microbiota• Atopic eczema• Probiotic and trial safety in infant populations• A role for probiotics in malnutrition and the developing world

WOMEN’S HEALTH

• Reducing the recurrence of urogenital infections in women• Probiotics in bacterial vaginosis• Vaginal microbiome

REGULATION AND PRODUCT DEVELOPMENT

• Examining the probiotic market in the Asia-Pacific region• Safety and QC• Strain identification, designation and safety• IP, regulation and GMP perspective• Clinical trials and health claim substantiation

CONFERENCE SYNOPSIS

SPONSORS & EXHIBITORS


Platinum Sponsor

Other Exhibitors & Sponsors

Silver Sponsors

Co-Hosts

Gold Sponsor

Japanese Society for Probiotic Science

Taiwan Association of Lactic Acid Bacteria

Supporter Supporting Partners

Media Partners

CONFIRMED SPEAKERS

WEI-LI WUAssistant Professor, Department of Physiology, College of Medicine, National Cheng Kung University, Taiwan

JACK GILBERTProfessor, Department of Pediatrics and Scripps Institution of Oceanography, University of California San Diego, USA / Co-Founder, The Earth Microbiome Project and American Gut Project

NICHOLAS WESTSenior Research Fellow , Mucosal Immunology Research Group, Griffith University, Australia

HOK BING THIOHead Residency program & Vice Chair, Department of Dermatology, Erasmus University Medical Center, Netherlands

NICOLE ROYPrincipal Scientist and Science Team Leader, AgResearch, New Zealand

YOSHIHISA YAMASHITAProfessor and Chairperson, Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth and Development, Kyushu University Faculty of Dental Science, Japan

YI-BING LINVice Chancellor, University System of Taiwan, National Chiao Tung University, Taiwan

DEV MITTARLead Scientist and Head of R&D ATCC, USA

NIKLAS LARSSONResearch Director, Probi AB, Sweden

CHRISTOPHE LAYSenior Scientist, Gut Microbiota, Danone Nutricia Research, Singapore

JOHN COMMONPrincipal Investigator, Skin Research Institute of Singapore (SRIS), Singapore

YUNN HWEN GANAssociate Professor, National University of Singapore, Singapore

CÉCILE CLAVAUDProject Leader, Research and Innovation Skin Microbiome Unit, L’Oreal, France

NIRANJAN NAGARAJANSenior Group Leader and Associate Director, Genome Institute of Singapore, A*STAR, Singapore

CHUN-MING ERIC HUANGChair Professor, Department of Biomedical Sciences and Engineering, National Central University, Taiwan

JQ LIUPrincipal Scientist, Procter & Gamble, Singapore

TZEHAU LAMScientist, Procter & Gamble, Singapore

MENGCHU WUCEO, Health GeneTech

MORTEN ISAKSENFounder and CEO, Bio-Me, Norway

LARRY WEISSCEO and Founder, Persona Biome

MARGARET MORRISProfessor and Head of Pharmacology, University of New South Wales, Australia

JAMES CHUCEO of GLORIA, National Central University, Taiwa

KARL FRASER Senior Scientist, AgResearch, New Zealand

WAYNE YOUNGSenior Scientist, AgResearch, New Zealand

MARK MORRISONChair and Professor, Microbial Biology and Metagonics, University of Queensland Diamantina Institute, Australia

ARTHUR OUWEHAND Technical Fellow and Research Manager, Global Health & Nutrition Sciences, DuPont Nutrition & Health, Finland

JIN-ZHONG XIAO General Manager, Next Generation Sequencing Institute, Morinaga Milk, Japan

UMA DEVI A/P PALANISAMY Associate Professor, Monash University, Malaysia

PATRICK LEEAssociate Professor, City University of Hong Kong, Hong Kong

ELIANA MARINO MORENOPrincipal Research Fellow and Immunology and Diabetes Laboratory Head, School of Biomedical Sciences, Monash University, Australia

ZARA JENNINGSAsia Pacific Business Development Manager, DNA Genotek

KENNETH GAOSenior Director, Corporate Development and Strategy, AssemblyBio, USA/China

SHAHRUL RAZID SARBINI Dean, Faculty of Agricultural and Food Sciences, Universiti Putra Malaysia

TETYANA ROCKSFernwood Foundation Research Fellow, Deakin University, Australia

CUONG D TRANSenior Research Scientist, CSIRO, Australia


CONFIRMED SPEAKERS

REBECCA SLYKERMANClinical Neuropsychologist and Senior Research Fellow, University of Auckland, New Zealand

ANDERS DAMHOLTHead of Clinical Development, Human Health Innovation, Chr. Hansen A/S, Germany

YING-CHIEH TSAIProfessor, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taiwan

ANDERS HENRIKSSONPrincipal Application Specialist, DuPont Nutrition & Health, Australia

PATRICIA CONWAYVisiting Professor, Nanyang Technology University (NTU), Singapore

TOH MINGZHANResearch Fellow, Food Science & Technology Programme, Department of Chemistry, National University of Singapore

BINDERYA GANZORIGCEO, Gyals Bio LLC, Mongolia

ANIR BATSUKHScientist, Gyals Bio LLC, Mongolia

LEE YEONG YEHProfessor of Medicine & Consultant of Gastroenterology, Hepatology & Internal Medicine, Universiti Sains Malaysia

JANET CHENSenior Research Scientist, Food Industry Research and Development Institute (FIRDI), Taiwan

YASUHIRO KOGAPresident, Japanese Society for Probiotic Science

DERON RAYMOND HERRScientific Advisor, Zymolo Inc, San Diego, USA and Associate Professor, National University of Singapore, Singapore

MARK HSIEHChairman of Board, Food Industry Research and Development Institute (FIRDI), Taiwan

CHERI CHUSenior Research Manager, Unilever Discover Shanghai

MING-JU CHENProfessor, Department of Animal Science and Technology, National Taiwan University, Taiwan

YONG JIANGCEO, America Diagnosis, Inc. USA

JOSHUA HSUScientist, America Diagnosis, Inc. USA

HANNA SIDJABATHonorary Fellow and Chief Investigator, University of Queensland Centre for Clinical Research, Australia

CONGRESS SCHEDULE DAY 1 WEDNESDAY 6TH MARCH 2019


Registration & Refreshments08:00-08:50 3rd Floor

MICROBIOME

Room: Ballroom A (3rd Foor)

PROBIOTICS

Room: VIP Room 5-7 (4th Floor)

Global Engage Welcome Address and Morning Chair’s Opening Remarks: Wei-Li Wu, Assistant Professor, Department of Physiology, College of Medicine, National Cheng Kung University, Taiwan

Global Engage Welcome Address and Morning Chair’s Opening Remarks: Rebecca Slykerman, Clinical Neuropsychologist and Senior Research Fellow, University of Auckland, New Zealand

KEYNOTE PRESENTATION:JACK GILBERT Professor, Department of Pediatrics and Scripps Institution of Oceanography, University of California San Diego, USA / Co-Founder, The Earth Microbiome Project and American Gut Project

Invisible Influence: The Microbiome and Human HealthThe human microbiome is quickly being recognized as a dynamic part of the human ecosystem, and research is starting to demonstrate that using ecology to understand this ecosystem has profound benefits for patient wellness. The immune system controls our interaction with the microbial world, and yet the microbial communities in our bodies are central to modulating the immune response. Changes in the human microbiome have substantial influence on atopy, neurological disorders, metabolic disorders, and a range of complex conditions and disease states. We will discuss evidence of these mechanisms of interaction and how we have started to disturb the delicate balance of the immune-microbe equilibrium, impacting the development and function of our immune systems. Central to this disturbance is the distance we have placed between our children and the microbial world, which has been demonstrated to have a substantial influence on their physiological, immunological, neurological and even endocrinological development. Applying new strategies to identify how the microbial ecosystem correlates with diseases states and treatment efficacy through Microbiome-Wide Association Studies (MWAS) is altering the trajectory of precision medicine, and providing a new framework for facilitating patient care.

09:00-09:35

SOLUTION PROVIDER PRESENTATION:NICHOLAS WESTSenior Research Fellow , Mucosal Immunology Research Group, Griffith University, AustraliaBuilding an evidence base for the clinical and mechanistic effects of a probiotic supplement for allergyAberrant regulation of immune activity by the microbiome is considered a key driver for the increasing prevalence of allergic rhinitis (AR). While modulation of the microbiome through probiotic supplementation may have clinical

benefit for AR, there is a need for supplement-specific clinical and mechanistic evidence before guidelines on the use of probiotics for AR can be issued. A key weakness in probiotic research identified by regulators is the lack of a systematic clinical development process to build evidence for the use of probiotic supplementation in disease. The aim of this study was to develop early phase clinical and mechanistic evidence to guide human clinical research on a multi-species supplement for AR (Ecologic® AllergyCare, Winclove Probiotics, The Netherlands). Physician confirmed AR patients consumed one sachet of 2 g freeze-dried multi-species probiotic supplement containing five bacterial strains twice daily for eight weeks. Utilising a Simon Two-Stage design, the primary outcome measure for a clinical benefit was a reduction in the mini-Rhinoconjuctivitis Quality of Life index of 0.7 of a scale-step. For the study to be considered a success ≥10 patients were required to experience a clinically beneficial response. A total of 40 participants completed the study. There were 25 participants (63%, 49-76%, P<0.001; mean, 95% confidence interval, P-value) out of 40 participants that had a clinically meaningful response to treatment based on assessment of mRQLQ. Significant reductions in symptom scores and overall AR severity was observed and there was a trend for a reduction in the frequency of allergy related medication. Nasal mucosa and blood samples collected pre- and post-supplement from a cohort of responders and non-responders were subsequently analysed for immune gene expression using Nanostring digital immune gene expression profiling to investigate inflammatory mechanisms mediating the beneficial effects of supplementation. Unsupervised hierarchical cluster analysis discriminated responders and non-responders in blood and nasal lysate at baseline, with HLA-C and ETS1 >1.5-fold higher (p<0.01) in peripheral blood in responders. There was a significant difference (p=0.03) in Th-1 cell score abundance between the groups from pre- to post-supplementation. Overall, the beneficial clinical effects of supplementation on AR warrant continued clinical investigation in phase 3 trials. AR responders to this probiotic supplement may have a T-cell mediated inflammatory endotype.

09:35-10:05

KEYNOTE PRESENTATION:ANDERS DAMHOLT Head of Clinical Development, Human Health Innovation, Chr. Hansen A/S, GermanyDevelopment of microbiome solutions, clinical trial design and evaluation of safety for consumers

At Chr. Hansen, our more than 3,150 employees are passionate about improving food and health. Our strategy is to expand the current knowledge within microbial solutions for human health e.g. LGG® being the world’s best documented probiotic strain. Chr. Hansen also own a significant number of specialty strains already in production and a bacterial strain collection of around 3,200 strains. Through our research program, we identify new product through screening and pre-clinical characterization of microbiome derived strains. Clinical trial demonstrates that a certain probiotic strain strengthens the defense against gut damage caused by regular use of household painkiller. With this clinical data, Chr. Hansen is breaking ground into a new field, unleashing the potential of probiotics as a safe and effective solution into new health areas. To do this, we focus on careful strain selection, high quality clinical trial design and professional evaluation of safety for consumers.

09:00-09:35


08:50-09:00

08:50-09:00



Morning Refreshments / Odd-Numbered Poster Presentations / One-to-One Meetings10:45-11:50 3rd Floor

KEYNOTE PRESENTATION:LI TSAI-KUNProfessor, National Taiwan University, TaiwanThe Translational Innovation and Intervention Platforms for Integrated Medical MicrobiotaIn recent years, many investigators in Taiwan and other countries have started to address the importance of microbiota, especially their corresponding critical roles in human health. Emerging aspects and topics including a historical opportunity for basic research, clinical application, disease prevention, and biotechnology products development have also been greatly recognised. However, entry barriers such as the relative high prices of next-generation sequencing (NGS), the lack of sophisticated bio-informaticians and statisticians for metagenomics analyses, the shortage of mature germ-free animal models and facilities, and the inexperience of fecal metabolites analyses in Taiwan metabolomics core labs, has greatly hindered basic and clinical scientists with interests from making their ideas into real experimental results! There are absolutely unmet needs to develop an interdisciplinary researcher-friendly platform for gut microbiota study in order to provide investigators in Taiwan a supportive and integrative system as well as expert consultation services for gut microbiota study. Through these platforms, we hope to offer better opportunities to researchers in Taiwan to help them develop their study design and achieve expected goals more efficiently and economically in the fields of gut microbiota (as an initiative) and human health research.

10:05-10:35

KEYNOTE PRESENTATION:CHUN-MING ERIC HUANG Chair Professor, Department of Biomedical Sciences and Engineering, National Central University, Taiwan Microbiome Banking and Editing with Electro-biotics

A commercial stool bank by collecting human gut microbiota is available in the market. Efforts from our group are devoted to establish a “Skin Microbiome Bank” for development of novel skin probiotics and/or prebiotics. The microbes within a human microenvironment may compete with each other for the same carbon source of fermentation. Microbiome editing by targeting individual bacterial species in the microbiome using bacteria-specific carbon source is our strategy to restore a health-associated microbiome after dysbiosis. The conjugates of carbohydrates and polymers provide unique carbon sources (prebiotics) for specific skin probiotic bacteria. Our recent results have demonstrated that skin bacteria can yield electricity during the bacterial fermentation. By using electrogenic bacteria, we develop new technology derived from the concept of probiotic-prebiotic-postbiotic-“electrobiotic”. Next-generation sequencing (NGS), although it is a new approach to biomarker identification, may not be able to dynamically detect the dysbiotic microbiome. We here introduce the technology of ”electrobiotic” for profiling and monitoring the skin dysbiosis in real time.

10:05-10:35

Room: Ballroom A (3rd Foor) Room: VIP Room 5-7 (4th Floor)

10-MINUTE POSTER PRESENTATION AWARD CEREMONY

10:35-10:45


NICOLE ROYPrincipal Scientist and Science Team Leader, AgResearch, New ZealandThe COMFORT cohort:

Identifying biomarkers for gut-brain axis relevant to functional gut disordersThe links between food, gut function and comfort, and brain function are at the forefront of nutritional research. Irritable Bowel Syndrome (IBS) is a functional gut disorder characterised by chronic or recurrent abdominal discomfort mostly associated with changes in gut habit in the absence of a detectable organic cause. Several central and peripheral mechanisms initiate perturbations in gut motor and sensory functions and lead to IBS symptoms. Peripheral molecules, and associated pathway dysfunctions and altered tissue metabolism, are important to better define functional gut disorders. In a case-control study, individuals with functional gut symptoms (cases) or asymptomatic (controls)

11:50-12:15

MICROBIOME IN HEALTH & DISEASES


Chair: Wei-Li Wu, Assistant Professor, Department of Physiology, College of Medicine, National Cheng Kung University, Taiwan

YOSHIHISA YAMASHITAProfessor and Chairperson, Section of Preventive and Public Health Dentistry,

Division of Oral Health, Growth and Development, Kyushu University Faculty of Dental Science, JapanOral dysbiosis related to acetaldehyde productionOral flora is the most expected candidate for acetaldehyde (ALD) causing oral or oropharyngeal cancer. Although Neisseria species are well know to be high amount-producers of ALD in vitro, no information is available regarding oral microbiota profiles related to ALD production. The salivary microbiota from 100 healthy males were classified into two types of communities (A and B) using 16S rRNA gene sequencing. ALD production was significantly higher in the type A community, while relative abundance of Neisseria species was significantly lower in this type community. Even if adjusted

11:50-12:15

MICROBIOME R&D & OUTSIDE THE GUT

Room: VIP 1 (4th Floor)

Chair: Hok Bing Thio, Head Residency program & Vice Chair, Department of Dermatology, Erasmus University Medical Center, Netherlands


Microbiota-Gut-Brain Axis, Psychobiotics and Neuropsychiatric DisordersPsychobiotics, a class of probiotics with psychotropic activities via the gut-brain axis. Lactobacillus plantarum PS128 is a novel psychobiotic, which normalized depression-like behaviors in early life-stressed mice and improved locomotion in Parkinson’s disease-like mice. In a 4-week, randomized, double-blind, placebo-controlled study investigated the effects of PS128 with autism spectrum disorder (n = 72), PS128 appeared to reduce scores for hyperactivity/impulsivity, opposition/defiance, anxiety, problems related to thoughts, and rule-breaking behaviors etc., whereas the placebo exerted insignificant effects. These results showed that PS128 is a feasible and natural intervention for

11:50-12:15

PROBIOTICS


Chair: Hanna Sidjabat, Honorary Fellow and Chief Investigator, University of Queensland Centre for Clinical Research, Australia



undergoing colonoscopy were recruited. Demographics, symptoms score, psychological score and dietary records were recorded. Metabolomics of biological samples, shotgun metagenomics sequencing of faecal samples and quantification of plasma neurotransmitters and bacterial metabolites were carried out to identify microbial and host factors and gain mechanistic insights into functional gut disorders.

11:50-12:15

for alcohol drinking and total amounts of salivary bacteria, the subjects with type A microbiota exhibited a significantly higher ALD production, as compared with those with type B microbiota. In addition, the relative abundance of Neisseria was negatively correlated with the acetaldehyde production (P = 0.001). We concluded that the salivary microbiota with lesser relative abundance of Neisseria species were independently associated with high ALD production, in spite of the high ALD production capacities of Neisseria species.

11:50-12:15

alleviating symptoms of neuropsychiatric disorders.

11:50-12:15YI-BING LIN Vice Chancellor, University System of Taiwan, National Chiao Tung University, TaiwanApplication of Artificial Intelligence to Earth Microbiome

12:15-12:40

DEV MITTARLead Scientist and Head of R&D ATCC, USADevelopment and evaluation of site-specific standards

for gut, skin, oral, and vaginal microbiome studiesThe human microbiome is a rapidly growing field of research with the potential to become one of the most important tools for personalized health and precision medicine. To date, a significant body of work has been performed on the human gut microbiome to evaluate its species composition and influence on physiology; this research has led to additional studies on microbiomes localized at other sites on the human body (e.g., skin, oral, vaginal). However, a predominant limitation in these site-specific microbiome studies is the lackof appropriate and relevant standards to control the technical biases introduced throughout the metagenomics workflow. To address this, ATCC has developed a set of genomic and whole cell mock microbial communities from fully sequenced and characterized ATCC strains that represent species found in the oral, skin, gut, or vaginal microbiome. To further enhance the use of these standards and eliminate the bias associated with data analysis, we have also collaborated with One Codex to develop data analysis modules that provide simple output in the form of true-positive, relative abundance, and false negative scores for 16S rRNA community profiling and shotgun metagenomics sequencing.

12:15-12:40

ANDERS HENRIKSSONPrincipal Application Specialist, DuPont Nutrition & Health, Australia

Dietary tools for shaping the gut microbiomeThere is a substantial pool of data demonstrating effects of a range of dietary components on composition of the gut microbiome. This presentation will elaborate on:• The effects of different dietary proteins

on the composition of gut microbiota, as well as reported health benefits of the such proteins.

• The role of human milk oligosaccharides in establishing an optimal microbiota early on in life, and

• Probiotics, which may deliver significant benefits even in the presence of a well-established gut microbiome.

12:15-12:40


SOLUTION PROVIDER PRESENTATION:NIKLAS LARSSONResearch Director, Probi AB, Sweden Probi Osteo® protects against bone loss

at lumbar spine in healthy early postmenopausal womenIn a recently conducted clinical study, Probi Osteo®, a combination of three probiotic bacteria from Probi, was shown to reduce the bone loss at lumbar spine in a population of early post-menopausal women. Bone health was measured as bone mineral density at lumbar spine by dual energy X-ray absorptiometry. It was shown that intake of the probiotic product for 12 months resulted in significantly less bone loss as compared to placebo (p<0.05). The difference between the groups was even more

12:40-13:10

SOLUTION PROVIDER PRESENTATION:HUE TRAN HORNIG-DOScientific Communication & Marketing Manager, Jennewein Biotech, Germany

Human Milk Oligosaccharides (HMOs) Novel food ingredients as old as mankindHuman milk oligosaccharides (HMOs) constitute the third largest component of breast milk and are unique to humans in concentration and structural diversity. HMOs possess several physiological effects; they confer protection against infectious diseases and act as prebiotics for the development of the infant microbiome. Today, it is widely recognized that the establishment of a healthy microbiome is key for the development of an infant. Failure to support a natural or

12:40-13:10



12:40-13:10

12:40-13:10

prominent in women with osteopenia and those with less than 6 years from the start of menopause.

healthy microbiome may potentially lead to obesity, autism or allergy development besides other current issues in infant health and development. HMOs are now available as ingredients for infant and general nutrition.

Luncheon / Poster Presentations / One-to-One Meetings13:10-14:10 3rd Floor

CHRISTOPHE LAYSenior Scientist, Gut Microbiota, Danone Nutricia Research, SingaporeEarly life nutrition and

its relevance in the first 1,000 days: A lifelong microbial journey perspectiveThe human gut microbiome is transmitted from one generation to the next. This transgenerational microbial inheritance occurs during pregnancy, during birth and during breastfeeding. Such vertical transmission contributes to educate our immature immune, metabolic and neurocognitive systems during foetal and early life, highlighting therefore the role of the microbiome in health and diseases. The first 1000 days of life is recognized as an important window to nurture child health and development and increasing body of evidence indicate that a compromised microbiome is a risk factor for the development of non-communicable diseases. Nutritional intervention could be harnessed as a mean to reduce the disease risk associated with a compromised microbiome.

14:10-14:35

MICROBIOME IN HEALTH & DISEASES



JOHN COMMONPrincipal Investigator, Skin Research Institute of Singapore (SRIS), SingaporeSkin microbiome

signatures in health and disease correlate with host immunity and microbial virulenceThe skin is a challenging ecosystem to study meta-omics due to thelow amount of biomass that can be recovered, which limits downstream techniques that are currently feasible on human subjects. We have recently been using metagenomics to investigate microbial communities present on the skin of atopic dermatitis patients to better understand shifts in community diversity and microbial functional characteristics. We can identify skin microbiome dermotypes that stratify groups of AD patients and observed that these groups correlate with host immunity and microbial virulence.

14:10-14:35

SKIN MICROBIOME



PATRICIA CONWAYVisiting Professor, Nanyang Technology University (NTU), Singapore

Effect of an inactivated bacterial preparation on colorectal cancer in an animal modelThe definition of probiotics specifies that it is a preparation of live microorganisms. However, studies have been presented using killed preparations and there are clearly benefits and reduced infection risk with killed preparations. This study explored the use of a killed bacterial preparation on colorectal cancer tumours. It has previously been shown that a preparation of heat inactivated Clostridium sporogenes can negatively impact on the growth of HCT116 and CT26 colorectal cancer cells in culture. It was therefore of interest to examine the impact of this preparation of heat inactivated C sporogenes on tumours in vivo. Using immunocompetent BALB/c mice, the preparation was tested for it impact on sub-cutaneously induced tumours. The preparation was found to exert a direct anti-tumour effect as observed by a decrease in the CT26 tumour volume and an improved survival rate of the mice. One group of mice with induced tumours and then treated with the preparation, and hence had reduced tumours, were re-challenged with an additional subcutaneous injection of the CT26 cells in the alternative flank. Tumours did not develop in these mice, indicative of a protective immune response. It was concluded that the heat inactivated C. sporogenes has the potential to be developed as a direct anti-tumour agent.

14:10-14:35

PROBIOTICS


Chair: Shahrul Razid Sarbini, Dean, Faculty of Agricultural and Food Sciences, Universiti Putra Malaysia

YUNN HWEN GANAssociate Professor, National University of Singapore, SingaporeFactors affecting

gut colonization and pathogenesis of hypervirulent Klebsiella pneumoniae, the causative agent of liver abscess diseaseHypervirulent Klebsiella pneumoniae is an emerging cause of community-acquired pyogenic liver abscess in parts of Asia such as South Korea, Singapore, Taiwan and Hong Kong. Hypervirulent isolates

14:35-15:00

CÉCILE CLAVAUDProject Leader, Research and Innovation Skin Microbiome Unit, L’Oreal, France

Dandruff and the scalp microbiomeSkin microbiome has positive impact on several aspects of human health, such as innate immune response modulation and protection against pathogens. Microorganisms interact with host keratinocytes and innate immune system,

14:35-15:00

JIN-SENG LINDirector, Culture Collection and Research Institute, SYNBIO TECH INC., TaiwanMicrobiome,

Probiotics and Exercise PerformanceThe human gut harbors a vast array of microorganisms that significantly affect host nutrition, metabolic function, gut development, and maturation of the immune system and epithelial cells. Recent studies also shown that gut microbiota may have a key role

14:35-15:00



are generally hypermucoviscous with the possession of a large virulent plasmid encoding rmpA and iron siderophores such as aerobactin. In Singapore and many parts of the world, K1 and K2 capsular types are the predominant hypervirulent isolates. In Klebsiella induced liver abscess (KLA), colonization by the bacteria is believed to precede translocation from the intestines to the liver. However, factors which predispose and facilitate the colonisation in the gut are not clearly defined. In our oral infection mouse model with a K1 capsular type, hypervirulent K. pneumoniae, we examine the role of probiotics administration after antibiotics treatment, as well as the role of capsule and fucose usage for efficient gut colonization. I shall discuss our results on each of these aspects as well as other factors that could contribute to the ability of the bacteria to establish an intestinal niche.

14:35-15:00

stimulating the secretion of antimicrobial peptides, free fatty acids, cytokines and chemokines, which might lead to adaptive immune responses. The skin microbiota contribute also to reinforce the skin barrier function (tight junctions, elicitation of antimicrobial peptides) and repair. Thus it is essential to understand how its disequilibrium contributes to skin conditions as for example scalp condition.Dandruff is one of the most common scalp conditions, affecting approximately half of adult population worldwide. This inflammatory chronic disorder is related to skin barrier disruption, epidermal cellular proliferation and differentiation, as well as shifts in sebum composition. It has been frequently associated with yeasts from Malassezia genus, which are also members of the healthy cutaneous microbiome. However, the microbial role has not been elucidated yet, and the etiology of the disorder remains incompletely understood. We used sanger and next-generation sequencing (NGS) to analyze bacterial and fungal microbiota associated with skin from normal and dandruff subjects. Microbial shift in Bacterial and fungal communities were observed in lesional and in non-lesional sites from dandruff subjects, suggesting that dandruff is related to a systemic process that is not restricted to the site exhibiting clinical symptoms. Our recent studies on dandruff scalp microbiota provides new perspectives for the understanding of this disorder, establishing steps toward a broader view of scalp health and the role of the microbiome in the symptom development.

14:35-15:00

in controlling the oxidative stress and inflammatory responses as well as improving metabolism and energy expenditure during intense exercise. Then modifying the microbiota through the use of probiotics could be a promising tool to improve exercise performance and energy availability. In this study we examined the effects of L. plantarum TWK10 (LP10) supplementation on exercise performance, physical fatigue, and gut microbial profile, and the data showed that LP10 significantly decreased final body weight and increased relative muscle weight (%). LP10 supplementation dose-dependently increased grip strength and endurance swimming time and decreased levels of serum lactate ammonia, creatine kinase and glucose after acute exercise challenge. Long-term supplementation with LP10 may increase muscle mass, enhance energy harvesting, and have health-promotion, performance improvement and anti-fatigue effects.

14:35-15:00

NIRANJAN NAGARAJANSenior Group Leader and Associate Director, Genome Institute ofSingapore, A*STAR, Singapore

Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environmentThere is growing attention surrounding hospital acquired infections (HAIs) due to high associated healthcare costs, compounded by the scourge of widespread multi-antibiotic resistance. Although hospital environment disinfection is well acknowledged to be key for infection control, an understanding of colonization patterns and resistome profiles of environment dwelling microbes is currently lacking. We report the first extensive genomic characterization of microbiomes (355), high-concern HAI-associated microbes (891) and transmissible drug resistance cassettes (2680) in a tertiary hospital environment based on a 2-timepoint sampling of 179 sites from 45 beds (4% of total). Deep shotgun metagenomic sequencing unveiled two distinct ecological niches of microbes and antibiotic resistance genes characterized by biofilm forming and human microbiome influenced environments that display

15:00-15:25

JQ LIUPrincipal Scientist, Procter & Gamble, Singapore TZEHAU LAMScientist, Procter & Gamble, SingaporeMetagenomics as a key tool for understanding the microbial basis of body odor in teenagers and kidsEven though human sweat is odorless, bacterial growth and decomposition of specific odor precursors in it is believed to give rise to body odor in humans. While mechanisms of odor generation have been widely studied in adults, little is known for teenagers and kids who have distinct sweat composition from immature apocrine and sebaceous glands, but are arguably more susceptible to the social and psychological impact of malodor. We integrated information from whole-microbiome analysis of multiple skin and multiple time points to perform the largest metagenome-wide association study to date on malodor. Correlations between odor intensity and the relative abundance of specific bacteria and the

15:00-15:25

TOH MINGZHANResearch Fellow, Food Science & Technology Programme, Department of Chemistry, National University of Singapore

Interactions between probiotic bacteria and yeasts: Potential applications in probiotic foodsThe health-promoting properties conferred by probiotics are contingent on the number of live microorganisms present in their delivery system at the point of consumption. As such, it is crucial that probiotic food products contain high levels of viable probiotic cells after manufacturing, and that adequate amounts are maintained throughout the distribution chain until it reaches the consumers. Various intrinsic and extrinsic factors can negatively influence the survival of probiotics in foods during production and storage, thereby diminishing the efficacy of the beneficial microorganisms. Recent studies have demonstrated that the co-existence of yeast and probiotic bacteria could enhance the viability of the latter under elevated temperature and acidic conditions. Therefore, the use of yeasts as an adjunct culture in probiotic foods could potentially improve the functional properties of these products. In this

15:00-15:25



corresponding patterns of divergence over space and time. To study common HAI-associated pathogens that were typically present at low abundances, a combination of culture enrichment and long-read nanopore sequencing was used to obtain thousands of high contiguity genomes (2347) and closed plasmids (2944), a significant fraction of which (>30%) are not represented in current sequence databases. Leveraging these high quality assemblies for characterizing resistance gene combinations and plasmid architectures revealed the dynamic nature of hospital environment resistomes and its untapped reservoirs. Phylogenetic analysis identified multiantibiotic resistant clonal strains as being more widely disseminated and stably colonizing across hospital sites. Further genomic comparisons with clinical isolates across multiple species supports the hypothesis that multidrug resistant strains can persist in the hospital environment for extended periods of time (>8 yrs) to opportunely infect patients. These findings highlight the importance of characterizing antibiotic resistance reservoirs in the hospital environment and establishes the feasibility of systematic genomic surveys to help target resources more efficiently for preventing HAIs.

15:00-15:25

associated metabolic pathway will be presented. The results showcase the power of skin metagenomics to study host-microbial co-metabolic interactions, identifying distinct pathways for odor generation from sweat in kids and teenagers, and highlighting key enzymatic targets for intervention.

15:00-15:25

presentation, the effect of yeasts on the growth of probiotic bacteria in different food matrices, and their survival at low pH conditions will be discussed. In addition, the implications of mixed yeast-bacteria fermentation on the organoleptic qualities of foods will also be covered.

15:00-15:25

COMPANY SHOWCASE:MENGCHU WUCEO, Health GeneTechTo know your second genome better

As the leading service and bioinformatics solution provider for high throughput genomic analysis in Taiwan, Health GeneTech (HGT) has experience in microbiome research for almost ten years. We helped investigators in Taiwan analyze microbiome in various samples including gut, skin, semen as well as environmental samples such as soil and air. In 2018, HGT introduced the latest Oxford Nanopore third generation sequencing technology to help the research community further deepen our understanding of the microbiome. In addition, to apply our knowledge in gut microbiome, HGT developed the “Direct-To-Consumer” gut microbiome profiling product together with customized probiotic supplements. It offers consumers new opportunity to examine and improve internal health condition with scientific evidence.

15:25-15:40

COMPANY SHOWCASE:MORTEN ISAKSEN Founder and CEOBio-Me, NorwayRapid and detailed analysis of the microbiome

Bio-Me have developed - in collaboration with Thermo Fisher Scientific - a new platform for rapid, high throughput, low cost and detailed analysis of the microbiome. Precision Microbiome Profiling (PMP) allows analysis of hundreds of samples down to species and strain level in less than a day. Bio-Me has recently conducted a demonstration study, which shows that species-level detection is necessary in order to detect lifestyle changes, and that daily variations at species level requires several timepoints for shaping in order to get an accurate picture of what is happening in the microbiome. PMP opens up for easy access to larger studies with multiple timepoints, leading to better documentation and understanding of the variations and contribution of the microbiome on health and disease.

15:25-15:40

COMPANY SHOWCASE:BINDERYA GANZORIG CEO, Gyals Bio LLC, MongoliaANIR BATSUKH Scientist, Gyals Bio LLC, MongoliaProbiotics in Mongolia and their Potential to Reach Global Markets Mongolia is located between Russia to the north and China. Products can reach out to the markets in Russia, China, middle east and other countries. We will introduce various probiotic products in Mongolia and illustrate you the markets where these probiotics are selling. Moreover, we will highlight you the unique features of probiotic products in Mongolia. The Research and Development of Gyals Bio LLC at novel probiotics for human health will be revealed.

15:25-15:40

Afternoon Refreshments / Even-Numbered Poster Presentations / One-to-One Meetings15:40-16:40 3rd Floor



MICROBIOME PROBIOTICS


Chair: Lee Yeong Yeh, Professor of Medicine & Consultant of Gastroenterology, Hepatology & Internal Medicine, Universiti Sains Malaysia

ROUNDTABLE DISCUSSIONS:Table 1: Gut-brain axisNICOLE ROYPrincipal Scientist and Science Team Leader, AgResearch, New Zealand

Table 2: Metagenomic data analysisNIRANJAN NAGARAJANSenior Group Leader and Associate Director, Genome Institute of Singapore, A*STAR, Singapore

Table 3: TherapeuticsLARRY WEISSCEO and Founder, Persona Biome, USA

Table 4: Microbiome and DietMARGARET MORRISProfessor and Head of Pharmacology, University of New South Wales, Australia

Table 5: Academic-industry collaborationJAMES CHU CEO, GLORIA, National Central University, Taiwan

16:40-17:05

ROUNDTABLE DISCUSSIONS:Table 1: Probiotics and diseasesREBECCA SLYKERMANClinical Neuropsychologist and Senior Research Fellow, University of Auckland, New Zealand

Table 2: Strain identificationJANET CHENSenior Research Scientist, Food Industry Research and Development Institute (FIRDI), Taiwan

Table 3: Business development & regulatory approachYASUHIRO KOGAPresident, Japanese Society for Probiotic Science

Table 4: Product formulation and delivery and academic-industry Collaboration KEN WUCEO, GLORIA, National Chiao Tung University, Taiwan

16:40-17:05


KARL FRASER Senior Scientist, AgResearch, New ZealandWAYNE YOUNGSenior Scientist, AgResearch, New ZealandMulti-omic Analysis of Metabolite Profiles in Human Plasma with the Fecal Microbiome: Providing Mechanistic Insight into Functional Gastrointestinal DisordersIrritable Bowel Syndrome (IBS) is a functional gastrointestinal (GI) disorder characterised by chronic or recurrent abdominal discomfort. In a case-control study, we aimed to identify microbial and host factors by integrating the metabolome and microbiome to provide mechanistic insights into functional GI disorders. A systems-level mechanistic understanding will assist in increasing the predictability of phenotypes for use in nutrition intervention studies. Individuals with functional GI symptoms (cases) or asymptomatic (controls) undergoing colonoscopy were recruited and 246 plasma samples were measured using LC-MS metabolomics, while 205 fecal samples were measured using shotgun metagenomics. Plasma metabolomic profiles differed significantly between the IBS phenotypes and the control subjects, with major perturbations observed in amino acid, bile acid and lipid metabolism. Microbial taxa that differed between IBS and control participants included Megasphaera, Blautia, and Bilophila. Canonical correlation analysis revealed associations (r>0.5) between numerous plasma lipids (e.g. diacylglycerolipids, triacylglycerolipids, and phosphatidylethanolamines) with Blautia and a group of unclassified Lachnospiracae. These two taxa were a major component of the microbiome, collectively accounting for >25% of the community. Similarly, correlations (r>0.7) were observed between plasma lipids and

17:05-17:35

DERON RAYMOND HERRScientific Advisor, Zymolo Inc, San Diego, USA and Associate Professor, National University of Singapore, Singapore Establishment of A Probiotic Microbiome Bank in the World

The term "normal microbial flora" denotes the population of microbes that inhabit the human organs of healthy normal persons. However, the normal microbial flora varies from region to region. Establishment of a probiotic microbiome bank in the world allows to compare the variation of normal microbial flora in different regions, enhancing the development of personalized food, cosmetics, and medicines. There has been tremendous progress at identification of probiotic/beneficial microbes in the gut. Our goal is to build up a probiotic microbiome bank which contains human beneficial microbes isolated from humans, plants and environments in the different regions of the world. Collaboration among microbiome associations in different countries is building up. Functions of probiotic microbes will be validated based on collaborations with academic and industrial partners. The bank will include live microorganisms, their genomes, proteomes, metabolites, and signals from microbes or hosts. The technology of artificial intelligence (AI) will be integrated with the probiotic microbiome bank for users to do “banking” of their own microbiome with others.

17:05-17:35


microbial genes involved in lipid and carbohydrate metabolism, including glyoxylate and dicarboxylate metabolism, and glycerolipid metabolism. Our results highlight links between major members of the fecal microbiome, in both composition and function, with the plasma metabolome in an IBS cohort. Integrated multi-omic analyses can reveal potentially critical mechanistic differences between subjects of different GI status.

17:05-17:35

17:05-17:35

End of Day One / Networking Drinks Reception17:35

MAKING A POSTER PRESENTATIONPoster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of $50 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.

POSTER COMPETITION – CLOSING DATE 8TH FEBRUARY 20191. Submit your entry prior to the closing deadline (1 entry per person)2. One winner from each Congress will be selected by the judge(s)3. The winners of the poster presentation will be given a 15-minute speaking position on the conference agenda and notified in advance of

the meeting4. The judge(s) will make the decision based on the abstract(s) submitted5. The winners will receive a certificate from the organisers6. Representatives from solution provider organisations are not eligible to enter the competition but are welcome to present posters at the

meeting as normal

**Poster space is limited so early submission is recommended

POSTER PRESENTATIONS

CONGRESS SCHEDULE DAY 2 THURSDAY 7TH MARCH 2019


Refreshments08:30-09:00 3rd Floor

MICROBIOME


PROBIOTICS


Morning Chair’s Opening Remarks: Wei-Li Wu, Assistant Professor, Department of Physiology, College of Medicine, National Cheng Kung University, Taiwan

Morning Chair’s Opening Remarks: Lee Yeong Yeh, Professor of Medicine & Consultant of Gastroenterology, Hepatology & Internal Medicine, Universiti Sains Malaysia

MARK MORRISONChair and Professor, Microbial Biology and Metagonics, University of Queensland Diamantina Institute, AustraliaNutritional ecology, the microbiome and digestive health

The digestive anatomy of humans can be described as a combinatorial system, where the large intestine provides a facultative afterburner: housing a mixture of microbes that can utilise both endogenous secretions as well as food components escaping proximal (host-mediated) digestion and absorption. In engineering terms, this site functions as a plug-flow digestor with microbial activities and ecosystem functions affected by a combination of nutrient availability and transit time. To date, the overwhelming amount of knowledge about diet x microbiome interactions has been generated by snapshot analyses, that is, by using extracts prepared from collected stool samples. By doing so, understanding the temporal changes in the microbiome during food digestion and transit remain limited in scope. Additionally, our knowledge of the mucosa-associated microbial communities, especially those of the upper gastrointestinal tract, are also underdeveloped; and perhaps, it can be considered the forgotten gut microbiome. For these reasons, innovations in sample collection, microbiota analysis and integration of the data with other clinical measures are all required if the promise and opportunities attributed to “microbiome research” are to be translated into gastrointestinal health and well-being. Here, I will present an overview of the “Brisbane approach” to building a conceptual framework of the role of the gastrointestinal microbiota in digestion, and their role in the clinical manifestations of digestive diseases. Our collective goal is to better predict and shape the impacts of the gut microbiota via the concepts of nutritional ecology: the study of how the nutrient milieu and its variations across temporal and spatial scales affects gut microbiota structure-function relationships. Continued progress needs to be made in these areas if the nutritional ecology of the gut is to be better managed, to restore and/or sustain gut homeostasis and resilience, and to reduce the social and economic burdens of digestive diseases and disorders.

09:00-09:30

KEYNOTE PRESENTATION:YASUHIRO KOGAPresident, Japanese Society for Probiotic SciencePrevention of periodontal diseases by an oral probiotic strain, Lactobacillus salivarius TI2711 (LS1)

The susceptibility of the host, the presence of pathogenic bacteria and the absence of “beneficial bacteria” are the main etiological factors of periodontal diseases. We have isolated Lactobacillus salivarius TI2711 (LS1) as an oral probiotic strain. Porphyromonas gingivalis is considered a major pathogenic bacterium causing periodontal diseases. LS1 completely killed P. gingivalis in a co-culture system at an input ratio of one to one-million. In a clinical study where subjects were daily administered 2x109 CFU LS1 for 4 weeks, the number of P. gingivalis in the subgingival plaque decreased to about one-tenth after 4-week-treatment.

09:00-09:30

LARRY WEISSCEO and Founder, Persona Biome How can we talk about health care when we don't understand health and we don't care?The emerging science of the microbiome is still in its infancy yet it is the driving force

behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps for our survival. It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision. I will discuss what we are learning about our biological past by studying the microbiota of minimally impacted hunter-gatherers in the Amazon and how it is challenging our deeply held ideas about human health that may inform our path forward.

09:30-10:00JIN-ZHONG XIAODirector, Next Generation Sequencing Institute, Morinaga Milk, JapanInsight into the reason of being of Bifidobacterium in human gutBifidobacterium is one of the major members

of the human intestinal microbiota which comprises thousands of bacterial species. The genus Bifidobacterium has been known to contain > 60 species/subspecies. Some of these bifidobacteria species are typical inhabitants of the human gut (designated as human-residential bifidobacteria, HRB) whereas others naturally colonise the guts of other animals (designated as non-HRB). This presentation will make some insight into the reason of being (how and why) of Bifidobacterium inhabiting the human gut, based on our new findings from genotypic and physiological studies.

09:30-10:00



SOLUTION PROVIDER PRESENTATION:ARTHUR OUWEHAND Technical Fellow and Research Manager, Global Health & Nutrition Sciences, DuPont Nutrition & Health, FinlandThe vaginal microbiota its composition and managementThe healthy vaginal microbiota is considered to be dominated by lactobacilli; although cultural and ethnic variations exist.

The most common Lactobacillus species are L. crispatus, L. gasseri and L. jensenii. L. iners is also commonly observed but the species has been suggested to have a dual role; both in health and disease. Bacterial vaginosis (BV) is a common condition that affects most women at some stage. BV is characterised by reduced levels of vaginal lactobacilli and an over growth of e.g. Gardnerella vaginalis and Atopobium vaginae. This imbalance is used in diagnosis with the so-called Nugent-score. Probiotic lactobacilli have been investigated as an adjunct to antibiotic treatment and shown to be successful. However, most studies have investigated the effect of vaginally applied probiotics. Here, I report on the development of the vaginal microbiota following antibiotic treatment for BV and the oral use of probiotics in BV. Two-week consumption of a combination of L. rhamnosus HN001 and L. acidophilus La-14 by healthy women, resulted in vaginal colonisation in 85% of the women. Interestingly, colonisation still increased in the week after consumption was stopped. In vitro studies have shown that both strains and in particular L. acidophilus La-14 produce hydrogen peroxide; an important antimicrobial involved in the stabilisation of a healthy vaginal microbiota. Both strains were also shown to inhibit the growth of G. vaginalis and A. vaginae in vitro and prevented experimental vaginosis in mice. In a subsequent human study, 40 women with borderline BV, as judged by Nugent-score of 4-6 and vaginal symptoms were randomised to receive either probiotic treatment or placebo for 15 days. In the probiotic group, Nugent-score improved to below 3 (no BV) with no change in the placebo group. Symptoms of itching and vaginal discharge also improved significantly in the probiotic group. As a complementary treatment to antibiotics for BV, the administration of L. acidophilus La-14 and L. rhamnosus HN001 was observed to improve recovery rate and reduce recurrence of BV. The combination of L. acidophilus La-14 and L. rhamnosus HN001 is beneficial in the management of BV.

10:00-10:30


Morning Refreshments / Poster Presentations / One-to-One Meetings10:30-11:30 3rd Floor

MICROBIOME


PROBIOTICS




PANEL DISCUSSIONS:A Step to Commercialisation: Building a Microbiome Network between Academics and Industry for Microbiome Discovery Efforts

NICOLE ROY (Moderator)Principal Scientist and Science Team Leader, AgResearch, New Zealand

JACK GILBERTProfessor, Department of Pediatrics and Scripps Institution of Oceanography, University of California San Diego, USA / Co-Founder, The Earth Microbiome Project and American Gut ProjectJIN-ZHONG XIAOGeneral Manager, Next Generation Sequencing Institute, Morinaga Milk, Japan

NIRANJAN NAGARAJANSenior Group Leader and Associate Director, Genome Institute of Singapore, A*STAR, Singapore

11:30-12:05

PANEL DISCUSSIONS:Towards Preventive Measures: Exploring the Current Market Trends and Regulatory Approach on Probiotics Use in Asia

PATRICIA CONWAY (Moderator)Visiting Professor, Nanyang Technology University (NTU), Singapore

CHUN-MING ERIC HUANG Chair Professor, Department of Biomedical Sciences and Engineering, National Central University, Taiwan


MARK HSIEHChairman of Board, Food Industry Research and Development Institute (FIRDI), Taiwan

11:30-12:05

MARGARET MORRISProfessor and Head of Pharmacology, University of New South Wales, Australia

Dietary modulation of the gut microbiome and behaviour – can we intervene?

12:05-12:30

MICROBIOME AND DIET


Chair: Uma Devi a/p Palanisamy, Associate Professor, Monash University, Malaysia

PATRICK LEEAssociate Professor, City University of Hong Kong, Hong Kong Neutral Processes Drive the Skin

Mycobiome Assembly over SeasonsFungi are key members of the human

12:05-12:30

SKIN MICROBIOME



CHERI CHUSenior Research Manager, Unilever Discover Shanghai Microbiome Innovation in Beauty & Personal

Care: From Science to ProductsIn recent years, groundbreaking

12:05-12:30

PROBIOTICS





Our work has demonstrated that rats fed an obesogenic, cafeteria style diet consistently show deficits in hippocampal dependent memory tasks, and reduced diversity of their gut microbiome compared to control rats. Such behavioural deficits were independent of weight differences, as rats consuming diets high in saturated fat or high in sugar, for just two weeks, had impaired spatial memory even while consuming similar amounts of energy as control rats on a regular diet. We found that the memory deficits were associated with changes in the gut microbiota composition and genes related to inflammation in the hippocampus, which is a key brain region for memory and learning. More recently we have investigated whether the bacteriostatic antibiotic, minocycline, which is reported Our work has demonstrated that rats fed an obesogenic, cafeteria style diet consistently show deficits in hippocampal dependent memory tasks, and reduced diversity of their gut microbiome compared to control rats. Such behavioural deficits were independent of weight differences, as rats consuming diets high in saturated fat or high in sugar, for just two weeks, had impaired spatial memory even while consuming similar amounts of energy as control rats on a regular diet. We found that the memory deficits were associated with changes in the gut microbiota composition and genes related to inflammation in the hippocampus, which is a key brain region for memory and learning. More recently we have investigated whether the bacteriostatic antibiotic, minocycline, which is reported to exert anti-inflammatory effects, can modulate spatial memory. Again, the cafeteria diet produced persistent deficits in spatial memory (novel place recognition) that were prevented by minocycline cotreatment. Of interest, chow rats treated with minocycline performed worse than those treated with vehicle. Faecal microbiota alpha diversity was reduced by both cafeteria diet and minocycline, but these reductions were not associated with performance on the novel place task. However, abundances of specific OTUs within Bacteroides and Lactobacillus were associated with place task performance. Together, studies such as these suggest the gut microbiota could play a causal role in regulating behaviour. Current experiments are exploring the impact of faecal transfer on memory performance in rats consuming the obesogenic diet.

12:05-12:30

skin microbiota, but we know less about them compared to bacteria. In this work, the seasonal dynamics and assembly of skin mycobiomes of a healthy Chinese cohort were investigated. Significant differences in community composition between individuals were found and the community composition variation within an individual grew over time. We found that within a season, the occurrence frequency of a large number of taxa fitted the neutral model, indicating that passive dispersal and ecological drift are major forces influencing the community assembly. Across four seasons, conditionally rare taxa were detected, and these taxa were consistently selected against in the neutral model. Co-association network analysis indicated that taxa selected by the host skin environment were important to the community network. Overall, microbial ecological theory can aid our understanding of the assembly of skin microbiota.

12:05-12:30

advances in Genomic sequencing technologies have significantly improved our ability to measure and identify microbes in, on and around us. This has led to a rapid expansion in our understanding of the role of the microbiome in human physiology in health & disease. As a unique body niche, the skin is home to a characteristic combination of microbial species that have pretty much taken over any available real estate on the body. The skin microbiome shows significant diversity of taxonomy across different regions of the skin as well as between individuals. Evolving scientific consensus has started to consider this skin microbiome as an integral part of the skin physiology. Understanding the relationship among microbes and between microbe and skin biology is important to drive our understanding of skin beauty & health thereby driving product innovations with a very different lens. Strategies to translate fundamental research into consumer facing market innovations will unlock huge potential of skin microbiome research for the Beauty and Personal Care industry.

12:05-12:30

ELIANA MARINO MORENOPrincipal Research Fellow and Immunology and Diabetes Laboratory Head,

School of Biomedical Sciences, Monash University, AustraliaFighting Fire with Fiber: The role of Diet and Gut Microbiota in DiabetesThe globally rising incidence of T1D and T2D and many inflammatory diseases are associated with altered gut microbiota or dysbiosis. In turn, there is a considerably

12:30-12:55

HOK BING THIOHead Residency program & Vice Chair, Department of Dermatology, Erasmus University Medical Center, Netherlands

Microbiome, Immune System and PsoriasisPsoriasis is a chronic immune-mediated inflammatory skin disease that affects about 2% of the world's population. It arises in genetically predisposed individuals. Both the skin and the gut microbiome influence the development

12:30-12:55

MING-JU CHENProfessor, Department of Animal Science and Technology, National Taiwan University, Taiwan

Shaping body weight through manipulating gut microbiome with probioticsSurprisingly, two kefir probiotics, Lactobacillus mali APS1 (APS1) and L. kefiranofaciens M1 (M1), exhibited completely opposite results in anti-obesity. APS1 manipulated the gut

12:30-12:55

alteration in the production of microbial short-chain fatty acids (SCFAs). SCFAs are produced in the large bowel through bacterial fermentation of dietary fiber and play an important role in maintaining gut mucosal immunity and a balanced gut microbiota ecology. SCFAs, particularly acetate and butyrate, show beneficial immunomodulatory effects contributing to the prevention of inflammatory and autoimmune diseases. A change in diet towards processed food, high in fat and meat protein, can significantly alter the composition of gut microbiota and adversely affect the intestinal immune system that can lead to metabolic dysfunction. The gut microbiota produces short chain fatty acids (SCFAs), which have been reported to exert a wide range of anti-inflammatory benefits. We showed that alterations in diet and gut microbial ecology underlie the pathogenesis of type 1 diabetes (T1D). In the non-obese diabetic (NOD) mouse, we found high concentrations of bacterial metabolites acetate and butyrate in blood and faeces correlated with protection from disease. We employed specialised high acetate- and butyrate-yielding diets, which also significantly increased number of Tregs, reduced the frequency and number of auto-reactive CD8+ T cells, correlated with changes in intestinal microbial composition and diversity and improved gut epithelial integrity.

12:30-12:55

and function of immune system. Studies on the cutaneous microbiome show a trend toward an increased relative abundance of Streptococcus and a decreased level of Propionibacterium in patients with psoriasis compared to healthy controls. In the gut microbiome, the ratio of Faecalibacterium prausnitzii and Escherichia Coli (F:E index) was perturbed in psoriatic individuals compared to healthy controls. Modulating the gut and skin microbiota can be beneficial in psoriasis.

12:30-12:55

microbiome’s obesity-associated metabolites, followed by regulation of lipid metabolism, enhancement of energy expenditure and inhibition of appetite. The specific hepatic metabolites induced by the APS1-manipulated gut microbiome also contributed to the amelioration of hepatic steatosis. While, M1 showed a reversed mechanism leading to higher body weight gain and body fat than their HFD counterparts. Our findings highlighted a possible microbiome and metabolome that contributed to shape the body weight and suggested that probiotics could serve as a potential therapy for modulating physiological function and downstream of the microbiota.

12:30-12:55

SOLUTION PROVIDER PRESENTATION:ZARA JENNINGSAsia Pacific Business

Development Manager, DNA GenotekStandardization vs. innovation in microbiome discovery: studying our most vulnerable populations illuminates the way.At face value, standardization and innovation may seem like opposing forces. This feels especially true given the pace of change in the microbiome field and the expectations that accompany such a large influx of discovery capital. But upon closer examination, it’s actually difficult to achieve the necessary and sufficient conditions of a true innovation (i.e. utility and lasting impact) without standardization (i.e. rigor and reproducibility). In this talk we will discuss how standardization enables innovation in different scenarios. First, we will outline some of the technical challenges encountered while studying vulnerable populations (infants, the elderly, IBD patients) and how we overcame them. Second, we will cover some of the current standardisation initiatives in the field of microbiome and how building on best practises can accelerate our progress toward meaningful innovation.

12:55-13:10

SOLUTION PROVIDER PRESENTATION:KENNETH GAOSenior Director,

Corporate Development and Strategy, AssemblyBio, USA/ChinaA Holistic Approach for Microbiome Therapeutic Development

12:55-13:10

SOLUTION PROVIDER PRESENTATION:YONG JIANGCEO, America Diagnosis, Inc. USAJOSHUA HSUScientist, America Diagnosis, Inc. USA Artificial intelligence (AI) for Electric Microbiome Profiling and a Quick DNA Analysis for Probiotic Identification The artificial intelligence (AI) has been used for profiling the electric spectra generated by human microbiome. App has been designed to online banking your microbiome. Big data of electric spectra are collecting based on collaboration with Dr. Eric Huang at National Central University (NCU) for future deep learning in smart phones. On the other hand, a GeneScanTM Precision DNA Analysis System has been developed for probiotic identification in samples with complex probiotic mixtures.

12:55-13:10





POSTER COMPETITION WINNERS TALKNA RAE SHIN & HOJUN KIMDepartment of Rehabilitation Medicine of Korean Medicine, Dongguk University, KoreaCombined effect of Scutellaria baicalensis with metformin on glucose tolerance via gut microbiota modulation in type 2 diabetes patients: A double-blind, randomized cross-over clinical trial

13:10-13:25

13:10-13:25

POSTER COMPETITION WINNERS TALKKYLIE HUANG, ENKHBAT ZAYABAATAR, AND ERIC HUANGNational Central University, TaiwanHigh-GABA rice induced by probiotic/endophyitic bacteria increases neuropeptide Y and reduces anxiety in mice

Luncheon / Poster Presentations / One-to-One Meetings13:25-14:25 3rd Floor

MICROBIOME AND DIET


PROBIOTICS


Chair: Uma Devi a/p Palanisamy, Associate Professor, Monash University, Malaysia


SHAHRUL RAZID SARBINI Dean, Faculty of Agricultural and Food Sciences, Universiti Putra MalaysiaPrebiotics: An Asian PerspectiveThe Asian region being the largest and most populous continent on earth, signifies most

diverse biological resource provides plentiful source of indigenous plants as prebiotic. This study will look at prebiotic plants that are available in Asia. An interesting source is sago starch, which is derived from palm (Metroxylon sagu) indigenous to South-East Asia, containing about 60 % resistant starch. Some in vitro and in vivo studies have demonstrated the ability of sago starch to increase numbers of Lactobacillus and Bifidobacterium. Studies on the effects of resistant starch on the glycemia index, insulin responses, and satiety have been continuously progressing, proving its role as a functional food. The Asian region also offers plentiful herbs and spices that are used as traditional medicines since ancient times. Most are due to their bioactive compounds i.e. polyphenols or flavonoids. Most polyphenols are of low bioavailability, where their influence on health may be either through intestinal absorption or interaction with colonic microbiota. Root of turmeric (Curcuma longa) is widely used as condiment in Asian food as well as a traditional remedy in Chinese and Indian Ayurvedic medicine. The curcuminoid are metabolised by colonic microbiota, modulating the bacterial population and their metabolic activity.

14:25-14:50

REBECCA SLYKERMANClinical Neuropsychologist and Senior Research Fellow, University of Auckland, New ZealandProbiotic Supplementation of Pregnant Women and Infants: Relationships to

Psychological and Neurocognitive OutcomesPostnatal depression and anxiety affect a woman’s risk of ongoing psychological problems and relationship with her baby. We conducted a randomised, double-blind, placebo-controlled trial of the effect of Lactobacillus rhamnosus HN001 in 423 New Zealand women. Results showed a significant reduction in postnatal depression and anxiety symptoms. There is pre-clinical evidence suggesting the gut microbiome is involved in developmental outcomes in childhood. Longitudinal cohort studies of children followed from birth through childhood suggest early antibiotic exposure is associated with poorer neurocognitive outcomes. The area of probiotic supplementation for improved neurocognitive outcomes is emerging. Early trials have not consistently found beneficial effects of probiotics and research is continuing to answer question about the role that antibiotics and probiotics play in childhood neurodevelopment.

14:25-14:50

TETYANA ROCKSFernwood Foundation Research Fellow, Deakin University, AustraliaDiet and mental and cognitive health: role of the gut microbiomeGrowing body of evidence points to a strong

connection between everyday diet, brain function, mood and cognition across the lifespan. For example, nutritional exposure in maternal and early postnatal diet, as well as food habits in childhood are associated with behavioural and emotional problems in younger people. Dietary patterns in adulthood and later life show links with mental and cognitive health. One of the fascinating biological pathways that mediate these relationships is the gut-brain axis. Human gut microbiome is one of the most exciting new fields of research demonstrating mechanisms of action in the unique bidirectional relationship between the gut and the brain. There are several genetic and environmental determinants of healthy gut-brain axis; however, everyday diet is increasingly recognized as the dominant modifiable factor in the mix. Diets based on nutrient- and fibre rich foods are beneficial for gut health, while diets predominant in nutrient-poor foods, such as sugary, high-fat and processed foods, are detrimental for gut, and, consequently, mental and cognitive health.

14:50-15:15

LEE YEONG YEH Professor of Medicine & Consultant of Gastroenterology, Hepatology & Internal Medicine, Universiti Sains Malaysia Effects of environment insults on gut-brain axis and using probiotics for its restoration

The use of probiotics can relieve gut symptoms and psychological disturbance through restoration of microbial balance and the gut-brain axis. Recent research has shown an intricate relationship between host gut wall and luminal microbiota environment which is critical in maintaining gut health and psychological well-being. Some factors have been shown to affect gut microbiota, but environment is probably most important, for example, diet rather than genes has been shown to be the primary determinant of gut enterotype and obesity in Asian populations. Disruption of a stable microbiota composition (dysbiosis) due to an environmental insult from e.g. major flood, typhoon and air pollution; common disasters in the Asian region, can lead to gut-brain axis disturbance in the form of irritable bowel syndrome and anxiety. Thus, this presentation aims to discover the effects of environment insults on gut-brain axis and how probiotics can possibly be used in such conditions.

14:50-15:15



CUONG D TRANSenior Research Scientist, CSIRO, Australia Changes in intestinal permeability modulates the gut microbiota populationIntestinal microbiota has been suggested to influence intestinal barrier strength, functional

integrity, and permeability regulation. However, the relationship between changes in intestinal permeability and its effects on the gut microbiota is less clear. This study aimed to investigate the changes in intestinal permeability and its influence of the gut microbiota in rats. 68 male Sprague-Dawley rats were randomised to 4 groups (n=4/dose/timepoint) and injected intraperitoneally (i.p.) with LPS: 0, 0.5, 1, 2 mg/kg. Animals were euthanized at 2, 4, 7, 10 days post-LPS administration. Animals were gavaged 24 hrs prior to cull with a dual sugar solution, lactulose (100 mg)/rhamnose (50 mg) (L/R), after a 12 hr fast for intestinal permeability assessment. Faecal and intestinal samples were collected for microbiota and short chain fatty acid (SCFA) analyses, and histological assessment, respectively. LPS administration increased plasma LPS levels by 30-fold on average on Day 2, returning to baseline by Day 4. Bodyweight was significantly (p<0.05) decreased by 5.9% on average vs. controls. Histologically, the most damaged intestinal region was jejunum>duodenum>ileum. Intestinal permeability (L/R ratio) was increased (p<0.05) in the 1 and 2 mg/kg groups (by 2.7- and 2.9-fold) vs. controls. ZO-1 staining intensity was decreased (p<0.05) by 5.2% in the 2 mg/kg dose on Day 4 vs. controls. On Day 2, SCFAs were increased (p<0.05) by 3-fold in the 2 mg/kg dose vs. controls. Total gut microbiota population was significantly (p<0.05) reduced in all LPS-treated groups vs. controls. Our findings suggests that increased intestinal permeability modulates the gut microbiota population.

15:15-15:40

HANNA SIDJABATHonorary Fellow and Chief Investigator, University of Queensland Centre for Clinical Research, AustraliaProbiotics for newborn babies: potential benefit to reduce the burden of neonatal sepsis

Probiotics types such as Lactobacilli and Bifidobacteria have been used for infants who have sepsis can be treated without any side effect. However, if the infants are in late stage of sepsis. probiotics can not be helpful outcome.The motility and maturity of gastric tract in neonatal can be improved by using probiotics. In this presentation, I will focus on the clinical trial applications of probiotics for newborn. There are several benefits of using probiotics for newborn babies: 1) The intestinal barrier resistant can be increased against the bacteria that crossing barrier and spread their poison. 2) modification the host reaction according to production of microbe; 3) mucosal response for IgA can be increased. 4) Anti-inflammatory such as Cytokines production can be raised. However, the benefit of probiotic activities relies on the dose in specific period time and on the species of bacterial strains.

15:15-15:40

WEI-LI WUAssistant Professor, Department of Physiology, College of Medicine, National Cheng Kung University (NCKU), Taiwan Gut microbiota regulates social behaviour via stress response pathways in the brainSocial impairment is a major symptom of neuropsychiatric conditions, such as autism spectrum disorder (ASD), schizophrenia, anxiety and depression. While the microbiome has been linked to social interaction in animals, gut-brain connections that regulate this complex behaviour remain entirely undescribed. Herein, we demonstrate that depletion

of microbiota in mice not only impairs social behaviour, but also activates specific brain regions related to canonical stress responses. Social deviation in germ-free and antibiotic-treated mice is associated with elevated levels of the stress hormone corticosterone, which is primarily produced via activation of hypothalamus-pituitary-adrenal (HPA) axis. Accordingly, removal of the adrenal gland, antagonism of the glucocorticoid receptor, and pharmacological inhibition of corticosterone synthesis effectively correct social deficits. Genetic ablation of the glucocorticoid receptor in specific brain regions and chemogenetic inactivation of hypothalamic neurons dramatically increase social behaviour. Further, we identify specific bacterial metabolites that suppress activation of the HPA axis and improve social impairment. These findings reveal that the gut microbiome regulates social behaviour by co-opting neuronal circuits that control stress responses in mice.

15:40-16:05

Closing Remarks / Conference Close16:05

TAIWAN MICROBIOME CONGRESS

6 - 7 M a r c h 2 0 1 9REGENT TAIPEI,TAIWAN

IN CONJUNCTION WITH 5TH MICROBIOME R&D AND BUSINESS COLLABORATION CONGRESS: ASIA AND 4TH PROBIOTICS CONGRESS: ASIA

Participating Organisations

SATELLITE MEETING

CONGRESS SCHEDULE

TAIWAN MICROBIOME CONGRESS: ASIA 2019

DAY 1 WEDNESDAY 6TH MARCH 2019

Registration & Refreshments08:00-08:50 3rd Floor

Room: VIP 8-10 (4th Floor)

Chair: Deron Raymond Herr, Associate Professor, National University of Singapore Co-Chair: Wilson Cheung, CEO, Bionefit Inc., USA

JEN-HER LUChief, Department of General Paediatrics, Veterans General Hospital, TaiwanProbiotics for Preterm Infants, Where is the Evidence

09:00-09:35

SHAWN YH CHENDirector, New Drug Development, Far East Bio-Tec co., Ltd., TaiwanThe cyanibacteria application on emerging viruses inhibition and future commericalization

09:35-10:05

DERON RAYMOND HERRPHD, Associate Professor, National University of Singapore, SingaporeLipidomic analysis of plasma sphingolipids in an East Asian population identifies novel associations with obesity- and diabetes-related characteristics

10:05-10:35

10-MIN OPENING REMARKS10:35-10:45

Room: Ballroom A

WILSON CHEUNGCEO, Bionefit Inc., USASkin Decoder

11:50-12:15


JOANNA WANGFounder, Phytopia, TaiwanPrebiotic benefits of essential oil and its application

12:15-12:40

YUH-SHYONG YANGProfessor, National Chiao Tung University, TaiwanSemiconductor based bacterial and cell sensors

12:40-13:05

Lunch / Poster Presentations / One-to-One Meetings13:05-14:05 3rd Floor


DR. CHIEN-LUNG CHEN, MDMD, Landseed Hospital SUNITA KESHARINational Central University, TaiwanMicrobiome metabolites for treatment of pruritus in patients with kidney dialysis

14:10-14:35

Chair: Battogtokh Chimeddorj, Associate Professor, M.D, Ph.D. Mongolian National University of Medical Sciences Co-Chair: Roger Liu, Biotools Co, LTD., Taiwan

CONGRESS SCHEDULE


DAY 1 WEDNESDAY 6TH MARCH 2019

BINDERIYA GANZORIGCEO, Gyals Bio LLCNARANBAT NYAMDAVAACEO and Professor, Gyals LLC, MongoliaProbiotic Research and Development in Mongolia

14:35-15:00

ROGER LIUCEO, Biotools Co. LTD., TaiwanThe Taiwan Gut Project

15:00-15:25

15 MINUTE COMPANY SHOWCASE:MANISH HARI National Central University, Taiwan ROGER LIU CEO, Biotools Co. LTD., TaiwanA Skin Probiotic Bank in Taiwan

15:25-15:40

Afternoon Refreshments / Poster Presentations / One-to-One Meetings15:40-16:40 3rd Floor

WEN-CHI CHENG R&D Director, General Biologicals Corp., TaiwanOral bacterial detection for periodontal disease prevention and monitoring

16:40-17:05

End of Day One / Networking Drinks Reception17:05

DAY 2 THURSDAY 7TH MARCH 2019

08:30-09:00 3rd Floor


Chair: Artem M. Guriev, Head of TIC SSMU, Russia Co-Chair: Chin-Chu Chen, Director, Grape King Bio, Taiwan

HENRY HORNG-SHING LUVP, National Chiao Tung University, TaiwanA pilot study of the influence of probiotics on hair toxic element levels after long-term supplement with different lactic acid strains

09:00-09:30

Refreshments

CHIN-CHU CHENDirector, Grape King Bio, TaiwanProbiotics as Supplements

09:30-10:00

SHIR-LY HUANGDirector, Institute of Microbiology and Immunology, National Yang-Ming University, TaiwanGut Microbiota and Autoimmune Diseases

10:00-10:30


PANEL DISCUSSION:Progress at Microbiome and Probiotic development in Taiwan

11:35-12:10

CONGRESS SCHEDULE


DAY 2 THURSDAY 7TH MARCH 2019

15 MINUTE COMPANY SHOWCASE:ALBERT JACKSON National Central University, TaiwanA Prebiotic Screening Platform

JUN TANAKAAPAC Sales, Human Metabolome Technologies Inc., Japan.Metabolomics and microbiome research

12:10-12:35

I-PING (IRENE) LINDirector of R&D Challenge Bioproducts Co., Ltd., Taiwan Enzyme biotechnology

12:35-13:0013:00-13:15

Lunch / Poster Presentations / One-to-One Meetings13:15-14:15 3rd Floor

ARTEM M. GURIEVHead of TIC, Smolensk State Medical University, RussiaClinical Microbiome Plan in Russia

14:15-14:45

Chair: Naranbat Nyamdavaa, CEO, Gyals LLC, Mongolia. Co-chair: Yong Jiang, CEO America Diagnosis, USA

15:10 YONG JIANGCEO, America Diagnosis, Inc., USAA Quick and Reliable System for Quantitative Categorization of the Microbiota Species in Human Specimen

15:25 JOSHUA HSUAI Architect, America Diagnosis, Inc., USAArtificial Intelligence (AI) for Microbiome Application

15:10-15:35

BATTOGTOKH CHIMEDDORJAssociate Professor, M.D, Ph.D., Mongolian National University of Medical Sciences, MongoliaANIR BATSUKHNational Central University, TaiwanBlood sugar regulating probiotic bacteria isolated from Mongolia Aaruul

14:45-15:10

CHI-CHANG HUANGProfessor, National Taiwan Sport University, TaiwanR&D of Probiotics as Ergogenic Aids

15:35-16:05

Closing Remarks / Conference Close16:45

TOBY HUANGBusiness Development, AllBio Science Inc., Taiwan Digital health and personalized genomics consumer products

16:05-16:45

Regent Taipei No. 3, Ln. 39, Sec. 2 Zhongshan N. Rd., Taipei 104, Taiwanwww.regenthotels.com/regent-taipei

The Regent Taipei Hotel offers luxurious accomodation, a dazzling array of signature dining and lifestyle amenities including a spa, health club, sauna and rooftop heated pool.

The hotel is located just a short walk from the city’s main attractions and accessible via excellent transport links.• In the heart of Taipei’s main commercial district• Overlooking the city and leafy parks• 50-minute drive from Taiwan Taoyuan International Airport• 5-minute walk to Zhongshan MRT station• Easily accessible via the Taipei main railway station

VENUE INFORMATION


DON’T DELAY, BOOK YOUR PLACE TODAY!Places are limited and are based on a first come, first served basis so to avoid disappointment contact us today

to reserve your place at Global Engage’s 5th Microbiome R&D and Business Collaboration Congress / 4th Probiotics Congress: Asia on 6-7 March 2019.

PHONE BOOKING+603 2117 5193

Our conference team will make all the necessary arrangements.

ONLINE BOOKINGVisit the website to book your place with credit card payment or an invoice request.

www.global-engage.com/event/microbiome-asiawww.global-engage.com/event/probiotics-asia

THE CONGRESS PACKAGE INCLUDES:All Conference Sessions

Lunches and RefreshmentsAccess to Exhibition Room

Networking Drinks ReceptionConference Workbook

E-Document Pack

HOTEL ACCOMMODATIONHotel accommodation will be available at a group rate.

Reuben Raj: [email protected] / +603 2117 5193www.global-engage.com

Asia Pacific Office: Global Engage Sdn Bhd, Level 33, Ilham Tower, No. 8 Jalan Binjai, 50450 Kuala Lumpur, Malaysia

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLEFor more details contact Reuben Raj: [email protected] Tel: +603 2117 5193

Follow Us

@Lifesciences_GE

5th microbiome r&d business collaboration congress · 5 th microbiome r&d & business...

Documents